David M. Hockenbery, MD

The bcl-2 oncogene and its role in apoptosis, mitochondrial biology and bioenergetic metabolism. Utilizes cell culture, transgenic mouse and protein biochemistry approaches for identification of cancer-selective metabolic pathways and discovery of small molecule inhibitors targeting these pathways.

Tzung S-P, Kim K, Basanez G, Giedt C, Simon J, Zimmerberg J, Zhang K, Hockenbery DM. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nature Cell Biol. 3: 183-191, 2001

Morrish F, Giedt C, Hockenbery DM. C-MYC apoptotic function is mediated by NRF-1 target genes. Genes and Development, 17: 240-255, 2003

O'Neill JW, Manion MK, Maguire B, Hockenbery DM. BCL-XL dimerization by three-dimensional domain swapping. J Mol Biol 356: 367-81, 2006

Schwartz PS, Manion MK, Emerson CB, Fry JS, Schulz CM, Sweet IR, Hockenbery DM. 2-methoxy antimycin reveals a unique mechanism for Bcl-xL inhibition. Mol Cancer Ther, 6:2073-80, 2007.

Margineantu DH, Emerson CB, Diaz D, Hockenbery DM. Hsp90 inhibition decreases mitochondrial protein turnover. PLoS One, 2:e1066, 2007.

Morrish F, Isern N, Sadilek M, Jeffrey M, Hockenbery DM. C-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry. Oncogene 28:2485-91, 2009. PMCID: PMC2779836.